Fig. 4

A The number of events prevented based on the HbA1c (red line), urinary-albumin-creatinine ratio (UACR) (purple line) clinical markers (green line), or clinical and novel biomarkers (blue line) strategy for the composite kidney outcome (defined as the composite of sustained 40% decline of eGFR, end-stage kidney disease with eGFR < 15 mL/min/1.73 m², or need for dialysis or kidney transplantation, or kidney death) outcome, and C-statistics obtained for the respective model. Numbers at each curve are specific HbA1c or UACR cut-offs, or based on 5–95th percentiles of predicted 5-year risk at specific treatment threshold. B The number needed to treat in order to avoid one composite kidney outcome according to the HbA1c (red line), UACR (purple), clinical markers (green line) or the clinical and novel markers (blue line) strategies are shown in the same figure. The intersection points at the vertical solid-line compares the number of events prevented or the number needed to treat (NNT) when 2809 patients are treated according to the HbA1c approach. The intersection points at the vertical dashed-lines compare the number of events prevented or the NNT when patients are treated according to UACR ≥ 30 mg/g (n = 1037) or UACR ≥ 300 mg/g (n = 214)